Medicare Advantage · Type 2 diabetes with chronic kidney disease · Versión completa en inglés: /pa-letter/medicare-advantage--t2d-ckd/
Carta de PA para Medicare Advantage: Type 2 diabetes with chronic kidney disease.
Plantilla defensible de carta para Ozempic (semaglutide) or Mounjaro (tirzepatide). T2D with CKD is one of the most defensible PA paths under the ADA Standards of Care and the KDIGO guidelines, which name GLP-1 RA as a preferred therapy for renal protection.
La carta misma está en inglés porque el revisor del plan la lee en inglés. La envuelve y la firma su clínico.
Cita de política: Plan-specific Medicare Advantage formulary and PA criteria.
Nota del plan: Medicare does not cover GLP-1 for obesity indication under federal statute (the 2003 MMA exclusion). For patients with documented type 2 diabetes, Medicare Advantage plans cover Ozempic and Mounjaro under the T2D indication. For patients with established cardiovascular disease and obesity or overweight, Medicare Advantage plans may cover Wegovy under the SELECT FDA-labeled cardiovascular indication (approved March 2024). For patients with moderate-to-severe obstructive sleep apnea and obesity, Medicare Advantage plans may cover Zepbound under the SURMOUNT-OSA FDA-labeled OSA indication (approved December 2024). The CV and OSA pathways follow FDA labeling and are evaluated against the plan's medical-necessity criteria for each indication.
Nota del plan: Medicare does not cover GLP-1 for obesity indication under federal statute (the 2003 MMA exclusion). For patients with documented type 2 diabetes, Medicare Advantage plans cover Ozempic and Mounjaro under the T2D indication. For patients with established cardiovascular disease and obesity or overweight, Medicare Advantage plans may cover Wegovy under the SELECT FDA-labeled cardiovascular indication (approved March 2024). For patients with moderate-to-severe obstructive sleep apnea and obesity, Medicare Advantage plans may cover Zepbound under the SURMOUNT-OSA FDA-labeled OSA indication (approved December 2024). The CV and OSA pathways follow FDA labeling and are evaluated against the plan's medical-necessity criteria for each indication.
Lo que OptumRx realmente requiere
Medicare Advantage contrata la administración del beneficio de farmacia a OptumRx, que adjudica esta PA. Los criterios siguientes provienen de la política clínica del PBM publicada públicamente. Cumpla cada uno antes de enviar.
- BMI greater than or equal to 30 with one comorbidity, OR BMI greater than or equal to 35 alone (post-2025 tightening)
- Six months of documented dietary intervention with structured weight-management program participation
- Step therapy through phentermine OR orlistat
- 6-month reauthorization checkpoint requiring documented weight loss greater than or equal to 4 percent from baseline
- Some employer carve-outs exclude obesity-indication GLP-1 entirely; check plan's specific formulary
La carta (copiar y editar)
Copie el cuerpo a continuación y péguelo en el portal de su clínico o procesador de textos. Reemplace cada marcador de posición entre [CORCHETES] con datos específicos del paciente antes de enviar. La carta es de su clínico al plan, firmada por su clínico.
[Today's date] Medicare Advantage (generic letter) Prior Authorization Department Submitted via: Plan-specific portal or CoverMyMeds Re: Prior Authorization Request, Ozempic (semaglutide) or Mounjaro (tirzepatide) Patient: [Patient full name] Member ID: [Plan member ID] Date of birth: [Patient DOB] Group number: [Group number if applicable] Prescriber: [Prescriber full name, NPI, DEA] Prescriber contact: [Phone, fax, email] To the Medicare Advantage (generic letter) Prior Authorization Reviewer, I am the treating clinician for [Patient name]. I am writing to request prior authorization for Ozempic (semaglutide) or Mounjaro (tirzepatide) for treatment of Type 2 diabetes with chronic kidney disease (ICD-10: E11.22, N18.3, N18.4, N18.5, N18.6). Clinical justification The KDIGO 2022 Clinical Practice Guideline for Diabetes Management in CKD names GLP-1 receptor agonists as a preferred second-line agent (after metformin and SGLT2 inhibitors) for patients with T2D and CKD, citing demonstrated renal-outcome benefit. The FLOW trial (semaglutide in T2D and CKD), published in NEJM in May 2024, randomized 3,533 adults with T2D and CKD (eGFR 25 to 75) to semaglutide 1.0 mg or placebo and demonstrated a 24 percent reduction in the composite kidney outcome (kidney failure, sustained eGFR decline of 50 percent or more, kidney or cardiovascular death) over a median 3.4 years. The ADA 2026 Standards of Care recommend GLP-1 RA independent of A1c for patients with T2D and CKD. Patient-specific findings - [Insert current measurements: weight, height, BMI, blood pressure] - [Insert relevant lab values with dates: A1c, lipid panel, kidney function] - [Insert documentation of comorbidities with ICD-10] - [Insert documentation of prior treatment history, including any prior GLP-1 trials, anti-obesity medication trials or lifestyle intervention] Criteria met per Medicare Advantage (generic letter) policy This request meets the criteria set out in Plan-specific Medicare Advantage formulary and PA criteria: - Diagnosis of T2D documented with ICD-10 E11.22 (T2D with diabetic chronic kidney disease) or E11.x plus N18.x - Most recent eGFR and urine albumin-to-creatinine ratio (UACR), with dates drawn - CKD stage documented (N18.3 = stage 3, N18.4 = stage 4, N18.5 = stage 5, N18.6 = ESRD) - Current A1c (within the past 90 days) - Nephrology consult letter or documentation of nephrology co-management (strengthens but not always required) Supporting evidence The clinical case for Ozempic (semaglutide) or Mounjaro (tirzepatide) in this indication is supported by the following registration trials and outcomes data: - FLOW (semaglutide in T2D and CKD), Perkovic et al., NEJM 2024, DOI 10.1056/NEJMoa2403347 - SUSTAIN-6 (semaglutide cardiovascular outcomes in T2D, included renal subgroup), Marso et al., NEJM 2016 - AMPLITUDE-O (efpeglenatide in T2D with CV or kidney disease), Gerstein et al., NEJM 2021 Plan-specific note Medicare does not cover GLP-1 for obesity indication under federal statute (the 2003 MMA exclusion). For patients with documented type 2 diabetes, Medicare Advantage plans cover Ozempic and Mounjaro under the T2D indication. For patients with established cardiovascular disease and obesity or overweight, Medicare Advantage plans may cover Wegovy under the SELECT FDA-labeled cardiovascular indication (approved March 2024). For patients with moderate-to-severe obstructive sleep apnea and obesity, Medicare Advantage plans may cover Zepbound under the SURMOUNT-OSA FDA-labeled OSA indication (approved December 2024). The CV and OSA pathways follow FDA labeling and are evaluated against the plan's medical-necessity criteria for each indication. Requested action I am requesting prior authorization for Ozempic (semaglutide) or Mounjaro (tirzepatide) at the [insert starting dose] starting dose, with planned titration per FDA labeling. I am also requesting that this authorization be granted for a continuous 12-month period subject to documented clinical response, per standard formulary practice. If additional information is required, please contact me directly at [Prescriber phone] or [Prescriber email]. I am available to discuss this case with your medical director if helpful. Thank you for your attention to this request. Sincerely, [Prescriber full signature] [Prescriber printed name, credentials] [Prescriber NPI] [Practice name and address] Attachments: - Current vital signs and BMI calculation - Most recent relevant labs - Documentation of comorbidities - Documentation of prior treatment trials - Sleep study report (if OSA indication) - Cardiac history documentation (if CV indication)
Aviso legal
Plantillas educativas únicamente. No constituyen asesoramiento legal ni médico. Las cartas deben ser firmadas por el clínico tratante (MD, DO, NP, PA) con autoridad de prescripción. Cada plan cambia los criterios trimestralmente. Verifique con el boletín de política de PA más reciente de su plan antes de enviar. No invente hallazgos clínicos. No altere la firma de un clínico.
Why you can trust GLP ChartSame scoring framework applied to every program. No paid placements. No removal of unfavorable information at advertiser request. Pricing is pulled from each program's public-facing page weekly.